Submit Your Feeds

Business News • PR NewsWire • CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI®

CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI®
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI®

SEATTLE, Sept. 17, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) and Servier today jointly announced that they have entered into an exclusive license and collaboration agreement to develop and commercialize PIXUVRI® (pixantrone) in a transaction valued at...

View More : http://www.prnewswire.com/news-releases/cti-biopharma-and-servier-announce-exclusive-license-and-collaboration-agreement...
Releted News by prnewswire
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI®
Los analizadores de baterías de la serie BT 500 de Fluke simplifican las pruebas de los sistemas de respaldo del suministro eléctrico para cargas críticas basados en baterías
Batterietester der Serie Fluke 500 vereinfachen die Prüfung betriebswichtiger Notstromversorgungssysteme
Home Sitemap Contact Us
© businessNewsNewsNews.com